
Wockhardt has high hopes for novel antibiotic Zaynich
Indian pharma group Wockhardt has completed a pre-filing meeting with the FDA and hopes to submit its new antibiotic Zaynich in the US and Europe later this year, eyeing a possible launch in fiscal 2026/27. Zaynich is based on cefepime, a well- …